pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease
Otsuka Beijing Research
Otsuka Beijing Research Institute
Otsuka Beijing Research clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 33
- Drugs
- 25
- Patents
- 0
Otsuka Beijing Research projects
7 ClinicalTrials.gov programs sponsored by Otsuka Beijing Research.
Otsuka Beijing Research has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Aripiprazole
Otsuka Beijing Research Institute
Schizophrenia
3 trials -
Cilostazol
Otsuka Beijing Research Institute
Cerebral Infarction
1 trial -
Cilostazol
Otsuka Beijing Research Institute
Polyneuropathy
1 trial -
Procaterol
Otsuka Beijing Research Institute
Asthma
1 trial -
Rebamipide
Otsuka Beijing Research Institute
Stomach Ulcer
1 trial -
Tolvaptan
Otsuka Beijing Research Institute
Hyponatremia and Extracellular Fluid in Cirrhotic
1 trial -
aripiprazole
Otsuka Beijing Research Institute
Bipolar Disorder
1 trial
Frequently asked questions
How many clinical projects does Otsuka Beijing Research have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.